Participation in the accelerator could help Dynocardia expedite the development of its ViTrack technology, which the company touts as a solution to problems stemming from inaccurate, intermittent (single-time-point) BP measurement and sub-therapeutic blood pressure management. Dynocardia also claims ViTrack holds great promise for improving the diagnosis and management of hypertension, a major cause of premature death worldwide.
The 3DExperience platform provides participants a community of mentors, industry professionals and peers to help them accelerate breakthrough technology and company growth, according to Dassault.
“We are so grateful to Dassault Systèmes for their interest in our work and their program’s support in our efforts,” said Dynocardia founder Dr. Mohan Thanikachalam in a news release. “We believe that their state-of-the-art prototyping facilities located here in Boston, along with Dassault Systèmes’ product-development-software portfolio, automated platform for clinical trial recruitment, and the bench strength of their engineering, IT, and design teams worldwide will allow us to commercialize ViTrack much faster than we’d have been able to otherwise.”
Dynocardia was founded in 2018 and could use the boost. A $2 million fundraising round announced in February 2020 has netted $2.09 million according to the company. A previous SEC filing had said the company had raised less money.